The shift from occasional satiety to consistent appetite reduction is one of the clearest before-and-after markers in the entire protocol
Dace Trence, MD, a professor emeritus of medicine at the University of Washington and the president of the American Association of Clinical Endocrinology, concurs that a chief benefit of generic GLP-1 medications is their cost-effectiveness
In November 2024, the Biden administration proposed expanding Medicare and Medicaid coverage for anti- obesity drugs, potentially extending coverage to an estimated 3.4 million Americans insured by Medicare and an additional four million by Medicaid
Labs required include CBC, BMP or CMP, TSH with T4, optional Lipid Panel, B12, and D3
22 UrsiniFMaiorinoMValenteMFerriLGregolinC